150 results on '"Camidge, D R"'
Search Results
2. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
3. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
4. Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330
5. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
6. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
7. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors
8. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
9. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
10. Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies
11. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
12. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
13. Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors
14. Supplement to: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
15. The epidemiology of self-poisoning in the UK
16. The causes of dysphagia in carcinoma of the lung
17. Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET Registry
18. Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
19. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
20. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
21. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) : An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
22. Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK plus) non small cell lung cancer (NSCLO) and brain metastases (BM) in the ascend-1 trial
23. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
24. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
25. RET rearrangements detected by FISH in 'pan-negative' lung adenocarcinoma
26. Abstract 927: Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686)
27. The impact of socioeconomic status on access to cancer clinical trials
28. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
29. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
30. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
31. Correlation of thymidylate synthase genotype and protein expression and association with lung cancer survival.
32. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
33. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
34. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
35. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.
36. A chronology of cancer
37. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).
38. A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
39. Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.
40. ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).
41. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).
42. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).
43. Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).
44. A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma).
45. A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).
46. Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors.
47. Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.
48. Radiation pneumonitis in small cell lung cancer: Impact of induction chemotherapy on estimated risk.
49. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.
50. A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.